Consent given pursuant to Sections 14 and 14A for the importation and supply of the therapeutic goods specified by Pfizer Consumer Healthcare

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the import, supply, and advertising of therapeutic goods to ensure they are safe, of high quality, and meet necessary standards. This legislation addresses the problem of ensuring that therapeutic goods available in the Australian market do not pose undue risks to public health and safety. Under the authority granted by this Act, the Therapeutic Goods Administration (TGA) has the power to consent to certain exceptions to the regulations, as evidenced by the case of Centrum Specialist Vision Plus AUST L 224881. The policy objective behind such consents is to balance public health protection with the availability of beneficial therapeutic goods, ensuring that products can be made available under specific conditions when they do not fully conform to prescribed standards. In the case of Pfizer Consumer Healthcare's application, the delegate of the Secretary, acting under subsection 14 and 14A of the Therapeutic Goods Act 1989, granted consent for the importation and supply of Centrum Specialist Vision Plus, which did not conform with the active ingredient content standards set out in TGO 78. The consent was subject to conditions designed to mitigate any potential risks, ensuring that the product's active ingredient content remained within acceptable limits. This decision highlights the TGA's role in managing and regulating therapeutic goods to protect public health while facilitating access to necessary products.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the supply, importation, or manufacture of therapeutic goods within Australia. These goods include medicines, medical devices, blood, and tissues, among others. The Act regulates the entire lifecycle of therapeutic goods, from research and development to post-market surveillance, and it applies across the Commonwealth, encompassing all states and territories. The Act is enforced by the Therapeutic Goods Administration (TGA), a department of the Commonwealth Government. However, the Act does not apply to goods that are exempt under specific provisions, such as those intended for personal use or for clinical trials. The scope of the Act can be extended through subordinate instruments, such as therapeutic goods orders and determinations, which provide detailed specifications and standards for various therapeutic goods. These orders and determinations can include standards for labelling, manufacturing practices, and the composition of therapeutic goods. In the specific case of the consent granted to Pfizer Consumer Healthcare for the importation and supply of Centrum Specialist Vision Plus AUST L 224881, the Act's application is evident in the regulation of the therapeutic claims and composition of the product. Despite the product not conforming to the specified standards for the content of the active ingredient 'Lutein', the TGA has allowed its supply under specific conditions to mitigate any potential risks to consumers. This action underscores the Act's role in balancing regulatory compliance with public health needs, ensuring that therapeutic goods available in the Australian market are safe and of acceptable quality.

Key Provisions

The key provisions of the Therapeutic Goods Act 1989, as demonstrated in this notice, involve granting specific consents for the importation and supply of therapeutic goods that do not fully comply with certain standards. In this instance, the Act allows the delegate of the Secretary of the Department of Health to provide consent for the importation and supply of Centrum Specialist Vision Plus, which does not meet the active ingredient content requirements set out in TGO 78 (section 14). This consent is given under section 14A of the Act and is valid until 15 January 2017. The consent provided ensures that the product can still be supplied to the market despite not fully adhering to the specified standards, but it is strictly regulated to maintain safety and efficacy. The obligations and requirements imposed by this consent on the parties involved, particularly Pfizer Consumer Healthcare, include adhering to the specific conditions set by the delegate of the Secretary. One such condition is that the content of the active ingredient 'Lutein' must fall within a range of 90.0% to 135.0% of the stated content on the product label (section 15(1)). This ensures that while the product may not fully conform to the standards, it remains within safe and acceptable limits to protect consumer health. The consent also mandates that the product must only be supplied for the duration specified, until 15 January 2017. In terms of breaches and consequences, any failure to comply with the conditions of the consent can result in serious ramifications. Although the Therapeutic Goods Act 1989 does not explicitly state the penalties for breaches of consent conditions within this specific notice, general provisions of the Act include potential civil or criminal penalties. For example, under section 29 of the Act, individuals or entities that supply non-compliant therapeutic goods can face fines and imprisonment. The maximum penalty for individuals can include a fine of up to $1,650,000 and imprisonment for up to 10 years, while for bodies corporate, the fines can reach up to $8,250,000. These penalties underscore the importance of adhering to the regulatory requirements and the potential severe consequences of non-compliance.